Syndrome with combined immunodeficiency

Syndrome with combined immunodeficiency is a broad grouping category used by Orphanet (ORPHA:331217) to classify a heterogeneous collection of rare genetic disorders characterized by defects in both the humoral (B-cell) and cellular (T-cell) arms of the adaptive immune system, occurring as part of a broader syndromic presentation. Unlike isolated combined immunodeficiency, these conditions feature additional clinical manifestations affecting other organ systems, which may include skeletal abnormalities, skin findings, neurological involvement, growth retardation, facial dysmorphism, or other congenital anomalies depending on the specific underlying syndrome. Patients with syndromic combined immunodeficiency typically present in infancy or early childhood with recurrent, severe, or opportunistic infections due to impaired immune function. The severity of the immunodeficiency can vary widely depending on the specific syndrome, ranging from severe combined immunodeficiency (SCID)-like presentations to milder forms. Additional features help distinguish individual syndromes within this category and guide genetic testing for a precise molecular diagnosis. Management depends on the specific underlying condition and the severity of immune compromise. Treatment strategies may include prophylactic antimicrobials, immunoglobulin replacement therapy, and in severe cases, hematopoietic stem cell transplantation (HSCT) to reconstitute the immune system. Supportive care addressing the non-immunological features of each syndrome is also essential. Early diagnosis through newborn screening programs (such as TREC-based screening) and genetic testing has improved outcomes for many of these conditions. Gene therapy is emerging as a treatment option for select disorders within this group.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Syndrome with combined immunodeficiency